Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLUCLORIC
2022-502019-12-00Phase 3Authorised
- Sponsor
- CHU de Nantes
- Start
- Apr 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing Clofarabine + busulfan with Fludarabine + busulfan (2 arms). Primary endpoint: Overall survival. Planned start Apr 2023; status: authorised.
02
Drugs
clofarabinefludarabinebusulfan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2022-502019-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502019-12-00.